ZVRA Zevra Therapeutics Inc
Price (delayed)
$7.66
Market cap
$414.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.28
Enterprise value
$441.04M
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes
Highlights
The quick ratio has surged by 104% year-on-year but it has declined by 17% since the previous quarter
Zevra Therapeutics's net income has shrunk by 129% YoY and by 18% QoQ
Zevra Therapeutics's EPS has shrunk by 75% YoY and by 8% QoQ
Key stats
What are the main financial stats of ZVRA
Market
Valuations
Earnings
Shares outstanding
54.12M
Market cap
$414.53M
Enterprise value
$441.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
10.31
Price to sales (P/S)
15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.68
Revenue
$23.61M
Gross profit
$16.2M
Operating income
-$87M
Net income
-$105.51M
EBIT
-$82.79M
EBITDA
-$76.4M
Free cash flow
-$69.67M
Per share
Balance sheet
Liquidity
EPS
-$2.28
EPS diluted
-$2.28
Free cash flow per share
-$1.51
Book value per share
$0.74
Revenue per share
$0.51
TBVPS
$2.26
Total assets
$178.13M
Total liabilities
$138.46M
Debt
$60.3M
Equity
$39.67M
Working capital
$51.96M
Debt to equity
1.52
Current ratio
2.53
Quick ratio
2.35
Net debt/EBITDA
-0.35
Margins
Efficiency
Dividend
EBITDA margin
-323.6%
Gross margin
68.6%
Net margin
-446.9%
Operating margin
-368.5%
Return on assets
-63.4%
Return on equity
-221.3%
Return on invested capital
-111%
Return on capital employed
-57.5%
Return on sales
-350.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZVRA stock price
How has the Zevra Therapeutics stock price performed over time
Intraday
4.64%
1 week
-2.42%
1 month
-4.37%
1 year
49.61%
YTD
-8.15%
QTD
2.27%
Financial performance
How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$23.61M
Gross profit
$16.2M
Operating income
-$87M
Net income
-$105.51M
Gross margin
68.6%
Net margin
-446.9%
ZVRA's net margin has dropped by 166% year-on-year and by 22% since the previous quarter
Zevra Therapeutics's net income has shrunk by 129% YoY and by 18% QoQ
The operating margin has plunged by 104% YoY and by 4% from the previous quarter
The operating income has plunged by 75% YoY
Growth
What is Zevra Therapeutics's growth rate over time
Valuation
What is Zevra Therapeutics stock price valuation
P/E
N/A
P/B
10.31
P/S
15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.68
Zevra Therapeutics's EPS has shrunk by 75% YoY and by 8% QoQ
The price to book (P/B) is 181% higher than the 5-year quarterly average of 3.5 and 45% higher than the last 4 quarters average of 6.8
Zevra Therapeutics's equity has decreased by 43% from the previous quarter and by 36% YoY
ZVRA's P/S is 33% above its 5-year quarterly average of 10.8 and 22% above its last 4 quarters average of 11.8
ZVRA's revenue is down by 14% YoY and by 3.6% QoQ
Efficiency
How efficient is Zevra Therapeutics business performance
Zevra Therapeutics's return on sales has shrunk by 116% YoY and by 2.5% QoQ
The company's return on assets has shrunk by 80% YoY and by 17% QoQ
Zevra Therapeutics's return on invested capital has shrunk by 52% YoY but it has increased by 25% QoQ
ZVRA's ROE is down by 31% QoQ
Dividends
What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZVRA.
Financial health
How did Zevra Therapeutics financials performed over time
The total assets is 29% greater than the total liabilities
The company's current ratio has surged by 114% YoY but it fell by 12% QoQ
The quick ratio has surged by 104% year-on-year but it has declined by 17% since the previous quarter
ZVRA's debt is 52% greater than its equity
The debt to equity has soared by 114% YoY and by 77% from the previous quarter
Zevra Therapeutics's equity has decreased by 43% from the previous quarter and by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.